The effects of MIAT down-regulation on promoting apoptosis could have implications for breast cancer therapy, since the mode of action of many chemotherapeutic drugs is largely dependent on their interaction with apoptotic signaling pathways. This evidence concerns the gene MIAT and breast carcinoma.